Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CCEL's Cash to Debt is ranked higher than
100% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 0.30 vs. CCEL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CCEL' s 10-Year Cash to Debt Range
Min: 0.17  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset -0.98
CCEL's Equity to Asset is ranked lower than
99% of the 207 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. CCEL: -0.98 )
Ranked among companies with meaningful Equity to Asset only.
CCEL' s 10-Year Equity to Asset Range
Min: -1.05  Med: -0.08 Max: 0.92
Current: -0.98
-1.05
0.92
Interest Coverage 1.72
CCEL's Interest Coverage is ranked lower than
81% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: 6.48 vs. CCEL: 1.72 )
Ranked among companies with meaningful Interest Coverage only.
CCEL' s 10-Year Interest Coverage Range
Min: 1.18  Med: 2.51 Max: 9999.99
Current: 1.72
1.18
9999.99
F-Score: 8
Z-Score: -0.95
M-Score: -4.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.31
CCEL's Operating margin (%) is ranked higher than
59% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 7.11 vs. CCEL: 9.31 )
Ranked among companies with meaningful Operating margin (%) only.
CCEL' s 10-Year Operating margin (%) Range
Min: -440  Med: -8.60 Max: 29.63
Current: 9.31
-440
29.63
Net-margin (%) 2.21
CCEL's Net-margin (%) is ranked lower than
57% of the 217 Companies
in the Global Medical Care industry.

( Industry Median: 3.47 vs. CCEL: 2.21 )
Ranked among companies with meaningful Net-margin (%) only.
CCEL' s 10-Year Net-margin (%) Range
Min: -460  Med: -11.70 Max: 23.26
Current: 2.21
-460
23.26
ROA (%) 4.20
CCEL's ROA (%) is ranked higher than
54% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 3.60 vs. CCEL: 4.20 )
Ranked among companies with meaningful ROA (%) only.
CCEL' s 10-Year ROA (%) Range
Min: -72.91  Med: -11.96 Max: 29.9
Current: 4.2
-72.91
29.9
ROC (Joel Greenblatt) (%) 188.72
CCEL's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 15.83 vs. CCEL: 188.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -340.07  Med: -24.24 Max: 187.03
Current: 188.72
-340.07
187.03
Revenue Growth (3Y)(%) 8.30
CCEL's Revenue Growth (3Y)(%) is ranked higher than
53% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. CCEL: 8.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CCEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.9  Med: 10.80 Max: 96.4
Current: 8.3
-17.9
96.4
EBITDA Growth (3Y)(%) 91.30
CCEL's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 123 Companies
in the Global Medical Care industry.

( Industry Median: 7.60 vs. CCEL: 91.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CCEL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -16.80 Max: 91.3
Current: 91.3
0
91.3
» CCEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CCEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 84.50
CCEL's P/E(ttm) is ranked lower than
87% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. CCEL: 84.50 )
Ranked among companies with meaningful P/E(ttm) only.
CCEL' s 10-Year P/E(ttm) Range
Min: 3.88  Med: 22.27 Max: 520
Current: 84.5
3.88
520
PE(NRI) 84.50
CCEL's PE(NRI) is ranked lower than
87% of the 149 Companies
in the Global Medical Care industry.

( Industry Median: 27.90 vs. CCEL: 84.50 )
Ranked among companies with meaningful PE(NRI) only.
CCEL' s 10-Year PE(NRI) Range
Min: 3.91  Med: 18.57 Max: 114
Current: 84.5
3.91
114
P/S 1.74
CCEL's P/S is ranked lower than
58% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. CCEL: 1.74 )
Ranked among companies with meaningful P/S only.
CCEL' s 10-Year P/S Range
Min: 0.28  Med: 1.36 Max: 5.1
Current: 1.74
0.28
5.1
PFCF 11.66
CCEL's PFCF is ranked higher than
79% of the 117 Companies
in the Global Medical Care industry.

( Industry Median: 24.04 vs. CCEL: 11.66 )
Ranked among companies with meaningful PFCF only.
CCEL' s 10-Year PFCF Range
Min: 4.27  Med: 16.25 Max: 125
Current: 11.66
4.27
125
POCF 11.66
CCEL's POCF is ranked higher than
66% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 15.33 vs. CCEL: 11.66 )
Ranked among companies with meaningful POCF only.
CCEL' s 10-Year POCF Range
Min: 3.2  Med: 12.66 Max: 277
Current: 11.66
3.2
277
EV-to-EBIT 15.39
CCEL's EV-to-EBIT is ranked higher than
66% of the 170 Companies
in the Global Medical Care industry.

( Industry Median: 19.71 vs. CCEL: 15.39 )
Ranked among companies with meaningful EV-to-EBIT only.
CCEL' s 10-Year EV-to-EBIT Range
Min: -90.3  Med: 6.00 Max: 182.9
Current: 15.39
-90.3
182.9
Current Ratio 1.02
CCEL's Current Ratio is ranked lower than
63% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. CCEL: 1.02 )
Ranked among companies with meaningful Current Ratio only.
CCEL' s 10-Year Current Ratio Range
Min: 0.47  Med: 1.56 Max: 35.3
Current: 1.02
0.47
35.3
Quick Ratio 1.02
CCEL's Quick Ratio is ranked lower than
58% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. CCEL: 1.02 )
Ranked among companies with meaningful Quick Ratio only.
CCEL' s 10-Year Quick Ratio Range
Min: 0.47  Med: 1.56 Max: 35.3
Current: 1.02
0.47
35.3
Days Sales Outstanding 68.44
CCEL's Days Sales Outstanding is ranked lower than
79% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 46.03 vs. CCEL: 68.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCEL' s 10-Year Days Sales Outstanding Range
Min: 13.89  Med: 50.53 Max: 128.82
Current: 68.44
13.89
128.82

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.27
CCEL's Price/Median PS Value is ranked lower than
62% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 1.11 vs. CCEL: 1.27 )
Ranked among companies with meaningful Price/Median PS Value only.
CCEL' s 10-Year Price/Median PS Value Range
Min: 0.29  Med: 1.28 Max: 84.38
Current: 1.27
0.29
84.38
Earnings Yield (Greenblatt) (%) 6.50
CCEL's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 4.20 vs. CCEL: 6.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCEL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 9.60 Max: 150.4
Current: 6.5
0.5
150.4

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Cryo-Cell International, Inc. was incorporated on September 11, 1989 in the State of Delaware. The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord9(r)) blood stem cells for family use. The Company has established private family cord blood stem cell banks in terms of the number of specimens preserved. Its headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations, including the processing and storage of specimens. The specimens are stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Oldsmar, Florida. It has expanded its research and development activities to develop technologies related to stem cells other than umbilical cord blood stem cells. During 2006, in parallel with its R&D associated with placental stem cells, the Company discovered novel technology related to menstrual stem cells. In November 2007, the Company announced the launch of its C'elleSM service related to this patent-pending technology, and the Company continues to focus its current research and development activities mainly on the C'elle service and related new menstrual stem cell technologies. The Company is actively marketing the C'elle service both through a bundled offer with the Company's U-Cord service and on a stand-alone basis. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, Lamaze instructors and other childbirth educators, certified nurse-midwives and other related healthcare professionals. To increase awareness among expectant parent audiences, the Company continues to promote its service in several national targeted prenatal magazines including American Baby and Fit Pregnancy, as well as several magazines distributed during childbirth classes. Expectant parents have also received information via emails and the Company has increased its internet marketing campaigns. Its competitors are Cord Blood Registry, Inc., ViaCord, a division of ViaCell, Inc., a wholly-owned subsidiary of PerkinElmer and LifeBankUSA, a division of Celgene. The Company is required to register with the FDA under the Public Health Service Act.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK